Clover Health
Offers wide-network Medicare Advantage plans powered by point-of-care physician software.
Something off on this page? Send us feedback.
Profile
Offers wide-network PPO and HMO Medicare Advantage plans, earning premiums while using Clover Assistant to bring patient data and care recommendations into physicians' workflows. Counterpart Health licenses the platform to external payors and providers, but insurance remains the sole reportable segment and depends on CMS-regulated Medicare economics.
Offers PPO and HMO Medicare Advantage plans across several U.S. states, with wide-network PPO coverage as the flagship product. Premiums generate nearly all revenue, while Clover Assistant brings claims, clinical, medication, and other patient data into physicians' workflows to support earlier identification and management of chronic disease.
Extends the platform outside its own health plans through Counterpart Health, which licenses Counterpart Assistant to other payors and providers. Clover Home Care complements the plan network with longitudinal, home-based primary care for members with complex needs.
Pairs broad physician choice with point-of-care data and a feedback loop between plan and provider information. Insurance remains the sole reportable segment, Counterpart is not yet material to overall operations, and results depend on CMS Medicare Advantage payments, quality ratings, benefit rules, and physician adoption.
Company facts
Categories
Key statistics
Year to date +75.3% · Average volume (30d) 4.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 6, 2026 | UBS | Reiterate | Neutral | $4.75 | $5 |
| Jul 21, 2026 | Canaccord Genuity | Reiterate | Buy | $4.20 | $5.50 |
| Jun 11, 2026 | UBS | Reiterate | Neutral | $4.75 | |
| Jun 4, 2026 | Canaccord Genuity | Reiterate | Buy | $2.50 | $4.20 |
| Oct 21, 2025 | Leerink Partners | Target | $3 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $0.04 | $0.05 | +29.4% | $728.3M | $743.2M | +2.0% | +12.56% |
| May 6, 2026Q1 FY26 | $0.07 | $0.07 | 0.0% | $714.9M | $749.2M | +4.8% | +5.22% |
| Feb 26, 2026Q4 FY25 | −$0.10 | −$0.05 | +51.0% | $467.1M | $487.7M | +4.4% | −2.79% |
| Nov 4, 2025Q3 FY25 | $0.02 | −$0.05 | −350.0% | $467.1M | $496.7M | +6.3% | −15.62% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $462.3M | $477.6M | $496.7M | $487.7M | $749.2M | $743.2M | |
| Gross profit | $108.9M | $99.6M | $73.2M | $74.2M | $159.5M | $153.0M | |
| Operating income | −$1.3M | −$10.6M | −$24.4M | −$49.3M | $27.3M | $28.0M | |
| Net income | −$1.3M | −$10.6M | −$24.4M | −$49.3M | $27.3M | $28.0M | |
| Diluted EPS | −$0.00 | −$0.02 | −$0.05 | −$0.10 | $0.05 | $0.05 | |
| Gross margin | 23.6% | 20.9% | 14.7% | 15.2% | 21.3% | 20.6% | |
| Operating margin | -0.3% | -2.2% | -4.9% | -10.1% | 3.6% | 3.8% |
Fiscal years (4-quarter sums)FY21 $1.47B · FY22 $3.48B · FY23 $1.46B · FY24 $1.37B · FY25 $1.92B
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $201.3M · Total debt $0 · Total assets $720.3M · Shareholders' equity $376.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 518.26M · Float 408.51M · 78.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 35.11M | 6.77% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 18.04M | 3.48% | 13F | Aug 13, 2026 |
| Geode Capital Management, LLC | 10.85M | 2.09% | 13F | Aug 12, 2026 |
| Vivek Garipalli · director, 10 percent owner: | 10.45M | 2.02% | Form 4 | Jan 9, 2026 |
| State Street Corp | 10.18M | 1.96% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Joseph Clay Thornton | officer: Interim CFO | −17,775 | $4.39 |
| Aug 10, 2026 | Andrew Toy | director, officer: Chief Executive Officer | −87,798 | $4.65 |
| Jul 20, 2026 | Karen Soares | officer: Chief Legal Officer | −51,700 | $4.51 |
| Jul 17, 2026 | Jamie L. Reynoso | officer: CEO, Medicare Advantage | −4,839 | $4.53 |
| Jul 15, 2026 | Joseph Clay Thornton | officer: Interim CFO | −4,630 | $4.67 |
Peers
- Humana
Heavyweight Medicare Advantage rival for senior plan members
- UnitedHealth Group
Largest MA brand rival with broad PPO, HMO and SNP coverage
- CVS Health
Aetna MA plans contest PPO/HMO members with CVS assets
- Elevance Health
Large MA and Carelon platform competitor
- Alignment Healthcare
Focused MA peer using senior-care technology and AVA
- Centene
Wellcare overlaps in government-sponsored MA and SNP plans
- Agilon Health
Physician enablement rival for MA value-based care
- Evolent
Payer/provider tech rival in value-based clinical enablement
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Clover Health | $4.22 | −0.12% | $2.19B | — | 60.1 | 0.9 | +55.6% |
| Humana | $386.23 | +0.16% | $46.30B | 36.5 | 31.2 | 0.3 | +26.2% |
| UnitedHealth Group | $392.50 | −0.12% | $356.86B | 25.3 | 18.4 | 0.8 | +0.4% |
| CVS Health | $93.07 | +0.02% | $118.74B | 24.6 | 11.5 | 0.3 | +7.3% |
| Elevance Health | $397.30 | +0.72% | $85.54B | 17.5 | 14.5 | 0.4 | +0.1% |
| Alignment Healthcare | $13.62 | −0.04% | $2.83B | 73.0 | 46.0 | 0.6 | +31.6% |
| Centene | $64.94 | +0.28% | $31.99B | — | 14.3 | 0.2 | +9.9% |
| Agilon Health | $92.54 | −0.02% | $1.54B | — | — | 0.3 | +7.2% |
| Evolent | $4.58 | −0.22% | $517.4M | — | 13.6 | 0.2 | +46.9% |
| Median | 25.3 | 14.5 | 0.3 | +8.6% |